Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.
about
Susceptibilities of anaerobic bacteria to cefoperazone and other antibioticsPharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiencyIn vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosaIn vitro activity of cefbuperazone against Bacteroides spp.Pharmacokinetics of cefoperazone in the parturient.Cefoperazone treatment of experimental endocarditis.Pharmacokinetics of cefoperazone in patients with neoplastic disease.BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.Comparative in vitro study in new cephalosporinsFactors affecting the in vitro activity of cefoperazone against the Bacteroides fragilis groupIn vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin.Comparative in vitro study of temocillin (BRL 17421), a new penicillin.Comparative activities of 13 beta-lactam antibioticsCefoperazone: regression analysis, disk content, and disk susceptibility testing considerations.Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.Aztreonam, cefoperazone, and gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis in rabbits.Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins.In vitro evaluation of pyridine-2-azo-p-dimethylaniline cephalosporin, a new diagnostic chromogenic reagent, and comparison with nitrocefin, cephacetrile, and other beta-lactam compounds.Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazoneCefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.Crystal structures of penicillin-binding protein 3 in complexes with azlocillin and cefoperazone in both acylated and deacylated forms.Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.In vitro and in vivo antibacterial activities of BO-1341, a new antipseudomonal cephalosporin.Biological activity of BO-1236, a new antipseudomonal cephalosporin.In vitro and in vivo activities of DN-9550, a new broad-spectrum cephalosporin.Comparative pharmacokinetics of cefoperazone and cefamandoleComparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli.Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.Bactericidal activity of cefoperazone with CP-45,899 against large inocula of beta-lactamase-producing Haemophilus influenzaeIn vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin.Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.Effects of moxalactam and cefotaxime on rabbit renal tissueAntimicrobial activity, pharmacokinetics, adverse reactions, and therapeutic indications of cefoperazone.Recognition and clinical significance of mechanisms of bacterial resistance to beta-lactams.Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.Effect of inoculum size and beta-lactamase production on in vitro activity of new cephalosporins against Haemophilus species.Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.
P2860
Q24628829-F056E36D-6D6D-4607-B180-245635FDF7C8Q30451386-EB32E924-2AFB-4247-8A11-0CD4BC1EC852Q35282939-87E25C68-8AAB-45C6-8999-3F19AFF70E60Q35299177-149BECF0-88F6-4E5C-AEA9-37C7AC88D1F6Q35640792-A4724731-FCC5-42DA-AB72-D62EE2DF9C54Q35645546-18873D40-14FF-49DD-9388-92C169B7C109Q35653699-8182179A-482B-4630-89C3-DACA49BB4806Q35669584-274DBB6F-08E8-4995-98BB-7D8AAE2DF324Q35670676-41C2B661-8F75-4C7B-A99C-9DE32971EE39Q35670880-BC16517E-B87B-4FEB-963F-E82D1CD26C7FQ35671193-F4CCA5F7-D2B9-40C9-B90A-F90E74B0E271Q35672511-1202DBF8-E40A-408D-9814-A71555EE148CQ35672612-5379CB13-405C-4401-B344-48B8F871A93CQ35675199-34354DFD-561C-45B7-8C6D-0AC71A5EE032Q35676188-37D86BF3-2BBE-42D6-879A-8CCEEE4DE715Q35717009-FE04EA45-9DF3-49B0-88B1-C67622248673Q35740078-08D8CD22-FF42-46C3-97C8-6118A3BF68B8Q35753847-E12D24F4-0BC8-40EB-A77F-98BA2BBE6FF0Q35761805-CBFB02B5-906B-4E65-A1A5-65A632148323Q37291333-FBCFCE71-3A8D-4E26-BB59-38626349EA43Q37291912-9AD01FAC-7275-457C-8C71-A77CADD7FFDEQ37291928-78F999D3-F33D-465E-B301-B60421F52BD6Q38600036-C0C1A0E5-E5E0-4012-BEE5-076557478029Q39817465-989A3DD5-8CDB-498B-9282-7C533A95DE6CQ39819826-8FCF99AD-E7BA-481A-89E0-E13330899717Q39828412-F7AAE05F-8D54-43E1-A85E-EAC9AB791FBBQ39849584-48E72F75-7C1D-4C8E-AB5F-9231C37EF40FQ39854563-C06C310D-A64C-410A-A477-03F86D0C3C8BQ39854709-894EB672-F004-47F2-A269-A415F58EBB55Q39854715-8C174904-5E31-4A72-87D4-1B91316270DEQ39855431-63BB78A3-D478-4767-8B86-1D3F09F1F503Q39855525-A0BA6D67-CD3E-4F5E-8382-34FC9AE0B23BQ39855932-7639F1AA-18F5-44AC-8E90-B70BA8C4123EQ39856285-D541602E-6DE3-4E63-9715-1A4539758244Q39857115-F7FF5367-A08C-4780-B631-C0707B31131BQ40114571-908946A8-7952-4552-AEF3-6522B73DAA89Q40215884-C9ACF4ED-7A9C-45BF-97FD-CFB6EC2CCBF8Q40281490-6BB80B88-4052-4444-BD3B-E4202A90581FQ40281640-D0D4501F-BD2C-4CFE-A9AD-F243526A80D6Q40281731-0DB4A2A0-0FCF-42AC-B2DF-D79D6BB2D9CC
P2860
Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
Comparative activity and beta- ...... e, a piperazine cephalosporin.
@en
type
label
Comparative activity and beta- ...... e, a piperazine cephalosporin.
@en
prefLabel
Comparative activity and beta- ...... e, a piperazine cephalosporin.
@en
P2093
P2860
P356
P1476
Comparative activity and beta- ...... e, a piperazine cephalosporin.
@en
P2093
P2860
P304
P356
10.1128/AAC.16.2.150
P407
P577
1979-08-01T00:00:00Z